Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
Recruiting now · Phase 1/Phase 2
Conditions studied: Solid Tumours
In brief
The purpose of this modular, first trial in human study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ascending dose levels (DLs) of AZD4956 monotherapy and in combination with other anti-cancer agents in participants with advanced/metastatic solid tumours with homologous recombination repair (HRR) deficiencies.
Key facts
- Study ID
- NCT07446855
- Run by
- AstraZeneca
- People needed
- 180
- Starts
- 2026-03-17
- Expected to finish
- 2030-03-29
- Last updated by the study team
- 2026-07-15
Who can join
Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Fairfax, Virginia, United States (enrolling)
- Research Site — Providence, Rhode Island, United States
- Research Site — Houston, Texas, United States
- Research Site — Melbourne, Australia
- Research Site — Westmead, Australia
- Research Site — Chūōku, Japan
- Research Site — Kashiwa, Japan
- Research Site — Seoul, South Korea
- Research Site — Seoul, South Korea
- Research Site — Barcelona, Spain
- Research Site — Barcelona, Spain
- Research Site — Barcelona, Spain
- Research Site — Logroño, Spain
- Research Site — Pozuelo de Alarcón, Spain
- Research Site — Seville, Spain
- Research Site — Cambridge, United Kingdom
- Research Site — London, United Kingdom
- Research Site — New York, New York, United States
- Research Site — Sutton, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.